134 related articles for article (PubMed ID: 15812530)
41. Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease.
Valcárcel D; Martino R; Piñana JL; Sierra J
Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S35-7. PubMed ID: 19561412
[TBL] [Abstract][Full Text] [Related]
42. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
[TBL] [Abstract][Full Text] [Related]
43. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
44. Hematopoietic stem cell transplantation for severe combined immunodeficiency diseases.
Cowan MJ; Neven B; Cavazanna-Calvo M; Fischer A; Puck J
Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):73-5. PubMed ID: 18162224
[TBL] [Abstract][Full Text] [Related]
45. Human leucocyte antigen-identical haematopoietic stem cell transplantation in major histocompatiblity complex class II immunodeficiency: reduced survival correlates with an increased incidence of acute graft-versus-host disease and pre-existing viral infections.
Renella R; Picard C; Neven B; Ouachée-Chardin M; Casanova JL; Le Deist F; Cavazzana-Calvo M; Blanche S; Fischer A
Br J Haematol; 2006 Sep; 134(5):510-6. PubMed ID: 16848795
[TBL] [Abstract][Full Text] [Related]
46. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
47. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
[TBL] [Abstract][Full Text] [Related]
48. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model.
Vanclée A; Lutgens LC; Oving EB; Deutz NE; Gijbels MJ; Schouten HC; Bos GM
Bone Marrow Transplant; 2005 Nov; 36(10):907-15. PubMed ID: 16151417
[TBL] [Abstract][Full Text] [Related]
49. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
[TBL] [Abstract][Full Text] [Related]
50. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation.
Seidel MG; Fritsch G; Matthes-Martin S; Lawitschka A; Lion T; Pötschger U; Rosenmayr A; Fischer G; Gadner H; Peters C
Haematologica; 2005 Oct; 90(10):1405-14. PubMed ID: 16219578
[TBL] [Abstract][Full Text] [Related]
51. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M
Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813
[TBL] [Abstract][Full Text] [Related]
52. Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
Okumura H; Yamaguchi M; Kotani T; Sugimori N; Sugimori C; Ozaki J; Kondo Y; Yamazaki H; Chuhjo T; Takami A; Ueda M; Ohtake S; Nakao S
Eur J Haematol; 2007 Feb; 78(2):157-60. PubMed ID: 17313562
[TBL] [Abstract][Full Text] [Related]
53. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
54. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia.
George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
Bone Marrow Transplant; 2007 Jul; 40(1):13-8. PubMed ID: 17450183
[TBL] [Abstract][Full Text] [Related]
55. Stem cell transplantation in primary immunodeficiency disease patients.
Sato T; Kobayashi R; Toita N; Kaneda M; Hatano N; Iguchi A; Kawamura N; Ariga T
Pediatr Int; 2007 Dec; 49(6):795-800. PubMed ID: 18045274
[TBL] [Abstract][Full Text] [Related]
56. Polysaccharide antibody responses are impaired post bone marrow transplantation for severe combined immunodeficiency, but not other primary immunodeficiencies.
Slatter MA; Bhattacharya A; Flood TJ; Spickett GP; Cant AJ; Abinun M; Gennery AR
Bone Marrow Transplant; 2003 Jul; 32(2):225-9. PubMed ID: 12838289
[TBL] [Abstract][Full Text] [Related]
57. Non-myeloablative stem cell transplantation for severe combined immunodeficiency--Omenn syndrome.
Rossi G; Zecca M; Giorgiani G; Bonetti F; De Stefano P; Locatelli F
Br J Haematol; 2004 May; 125(3):406-7. PubMed ID: 15086425
[No Abstract] [Full Text] [Related]
58. Fatal late-onset EBV-associated post transplant lymphoproliferative disease after umbilical cord blood transplantation due to persistent mixed chimerism and severe delay in T-cell recovery in a patient with Omenn's syndrome.
Meyer-Bahlburg A; Winkler J; Meerbach A; Holzhausen HJ; Wawer A; Diwan O; Wutzler P; Horneff G; Burdach S
Bone Marrow Transplant; 2004 Aug; 34(3):283-4. PubMed ID: 15195075
[No Abstract] [Full Text] [Related]
59. Outcome of children requiring intensive care following haematopoietic SCT for primary immunodeficiency and other non-malignant disorders.
Cole TS; Johnstone IC; Pearce MS; Fulton B; Cant AJ; Gennery AR; Slatter MA
Bone Marrow Transplant; 2012 Jan; 47(1):40-5. PubMed ID: 21358684
[TBL] [Abstract][Full Text] [Related]
60. Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism.
Eapen M; Ahn KW; Orchard PJ; Cowan MJ; Davies SM; Fasth A; Hassebroek A; Ayas M; Bonfim C; O'Brien TA; Gross TG; Horwitz M; Horwitz E; Kapoor N; Kurtzberg J; Majhail N; Ringden O; Szabolcs P; Veys P; Baker KS
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1438-45. PubMed ID: 22430083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
